MXI1

Across TCGA pan-cancer cohorts, MXI1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MXI1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher MXI1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MXI1 expression acts as an unfavorable survival marker.

SCLC and PRAD are the cancer types where MXI1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
PRAD	DFS	Median	All	0.085	0.774	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MXI1–SCLC (OS)

Open the SCLC breakdown →